lmb-100
mAbexperimentalADC
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 7, 2016 (NCT02798536)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 2
- Ascites · Phase 1
- Carcinoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cholangiocarcinoma · Phase 1
- Lung Neoplasms · Phase 2
- Mesothelin · Phase 1
- Mesothelioma · Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Pleural Effusion, Malignant · Phase 1
Mechanism of action
- MesothelinBINDING AGENT
Mesothelin binding agent
- Elongation factor 2DISRUPTING AGENT
Elongation factor 2 disrupting agent
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297777 ↗
Also known as
- lmb-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05375825 | Phase 1 | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT04840615 | Phase 1 | Jun 11, 2021 | National Cancer Institute (NCI) |
| NCT04027946 | Phase 2 | Jul 31, 2019 | National Cancer Institute (NCI) |
| NCT04034238 | Phase 1 | Jul 31, 2019 | National Cancer Institute (NCI) |
| NCT03644550 | Phase 2 | Oct 5, 2018 | National Cancer Institute (NCI) |
| NCT03436732 | Phase 1 | Feb 28, 2018 | National Cancer Institute (NCI) |
| NCT02810418 | Phase 1/Phase 2 (Phase 2) | Jun 10, 2016 | National Cancer Institute (NCI) |
| NCT02798536 | Phase 1 | Jun 7, 2016 | National Cancer Institute (NCI) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 8 | 8 | 2 | 2016 |
1 organizations
Page 1 / 1